References Oral semaglutide: An OASIS from injectables. The Lancet Diabetes & Endocrinology , 2023
Until a proper cardiovascular outcomes trial is completed for retatrutide, semaglutide remains the only compound in this class with proven cardiovascular benefit
For the 3,363 cases in MDL-3094 alleging gastroparesis, bowel obstruction, and other GI injuries, the letter supports the argument that the company knew about adverse events and failed to ensure they were properly reported
Its vital to eat a healthy diet and engage in regular exercise while taking them to see the best results
GLP-1s and Depression: Research Gaps Some of the uncertainty surrounding how GLP-1s influence mental health stems from early clinical trials
Lower glucagon levels can better regulate blood glucose, especially in people with type 2 diabetes